GNPX News and Press, Genprex Inc. From 10/16/20

The following slide deck was published by Genprex, Inc. in conjunction with this event. For further details see: Genprex (GNPX) Investor Presentation - Slideshow

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Economic reports in the week aheadBig banks will lead off the Q3 earnings season next week with investors likely to see more surprises than normal due to t...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX ), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, announced that it will be presenting virtually at the upcoming Z...

Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX ), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced that it will be presenting at the Alliance for R...

Gallagher’s appointment demonstrates the Company’s commitment to building a world-class intellectual property portfolio Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX ), a clinical-stage gene therapy company develop...

The arrival of COVID-19 caught everyone unaware, especially in the healthcare sector and it led to a shortage of respirators, face masks, and ventilators. The sudden lack of this equipment has made automobile manufacture to venture into the production of these special medical PPE and equipment...

Genprex (NASDAQ: GNPX) , a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, has appointed William E. Gannon Jr., MD, MBA, as vice president of Regulatory Affairs. With more than three decades of experience in the biot...

Dr. Gannon will oversee and manage regulatory matters for the Company’s upcoming clinical trials, including its lead drug candidate in combination with Tagrisso® for which Fast Track Designation was received earlier this year Genprex, Inc. (“Genprex” or the ...

LOS ANGELES, CA / ACCESSWIRE / August 31, 2020 / LD Micro today announced the final list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online. Registration details and the company schedule can be seen here: https://ld500.ldmicro.co...